Loading…
Lobbying Spend
—
Filings
38
Firms Hired
2
Active Period
2001–2018
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: W STRATEGIES, LLC
Education about the importance of access to innovative drug therapies. H.R.2430/S.934: FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $30,000
Matched citations: H.R.2430
Education about the importance of access to innovative drug therapies. H.R.2430/S.934: FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $30,000
Matched citations: S.934
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: W STRATEGIES, LLC
Education about the importance of access to innovative drug therapies. H.R.2430/S.934: FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $30,000
Matched citations: H.R.2430
Education about the importance of access to innovative drug therapies. H.R.2430/S.934: FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $30,000
Matched citations: S.934
Education about the importance of access to innovative drug therapies. S.3056: CREATES Act of 2016.
Client expense: — · Firm income: $30,000
Matched citations: S.3056
Education about the importance of access to innovative drug therapies. H.R. 34: 21st Century Cures Conference Report. S.3056: CREATES Act of 2016.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 34
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
2016 · fourth_quarter · Firm: W STRATEGIES, LLC
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client expense: — · Firm income: $30,000
Matched citations: H.R.5122
Education about the importance of access to innovative drug therapies. H.R. 34: 21st Century Cures Conference Report. S.3056: CREATES Act of 2016.
Client expense: — · Firm income: $30,000
Matched citations: S.3056
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
2016 · third_quarter · Firm: W STRATEGIES, LLC
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client expense: — · Firm income: $30,000
Matched citations: H.R.5122
Education about the importance of access to innovative drug therapies. S.3056: CREATES Act of 2016.
Client expense: — · Firm income: $30,000
Matched citations: S.3056
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
2016 · second_quarter · Firm: W STRATEGIES, LLC
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client expense: — · Firm income: $30,000
Matched citations: H.R.5122
Education about the importance of access to innovative drug therapies. S.3056: CREATES Act of 2016.
Client expense: — · Firm income: $30,000
Matched citations: S.3056
Pulmonary Hypertension Research Act of 2005
2006 · year_end · Firm: HOLLAND & KNIGHT LLP
S. 1774/HR 3005, Pulmonary Hypertension Research Act of 2005
Client expense: — · Firm income: $60,000
Matched citations: S. 1774
Source: Senate LDA